Showing 5191-5200 of 6036 results for "".
- Johnson & Johnson Vision Launches Tecnis Synergy and Tecnis Eyhance IOLs in Canadahttps://modernod.com/news/johnson-johnson-vision-launches-tecnis-synergy-and-tecnis-eyhance-iols-in-canada/2478160/Johnson & Johnson Vision announced Health Canada approval and July availability of its Tecnis Synergy and Tecnis Eyhance IOLs to the Canadian market. The Tecnis Synergy, originally launched in Europe in September 2019, delivers continuous high-cont
- Tom Frinzi Joins CorneaGen Board as Executive Chairhttps://modernod.com/news/tom-frinzi-joins-corneagen-board-as-executive-chair/2478159/CorneaGen announced that Tom Frinzi has joined the company’s board as executive chair. Mr. Frinzi brings more than 40 years of expertise in clinical-to-commercial transition and fostering next-level growth within small to mid-size private equity companies and Fortune 500 corporations. His
- Gyroscope Therapeutics Initiates Phase 2 Program Evaluating its Investigational Gene Therapy for Dry AMDhttps://modernod.com/news/gyroscope-therapeutics-initiates-phase-2-program-evaluating-its-investigational-gene-therapy-for-dry-amd/2478157/Gyroscope Therapeutics announced the initiation of its phase 2 program evaluating its investigational gene therapy, GT005, for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). GT005 is a one-time AAV-based gene therapy that is delivered under the r
- Alcon Broadens US Availability of MARLO Digital Platformhttps://modernod.com/news/alcon-broadens-us-availability-of-marlo-digital-platform/2478153/Alcon announced broader US availability of its MARLO digital platform offered within independent OD practice. The platform allows patients to order, reorder and track their Alcon contact lens order online and have their lenses shipped right to their doorstep, while keeping the relationship and re
- Russia’s Approval of Virus Vaccine Greeted With Some Alarmhttps://modernod.com/news/russias-approval-of-virus-vaccine-greeted-with-some-alarm/2478146/Russia on Tuesday became the first country to approve a coronavirus vaccine for use in tens of thousands of its citizens despite international skepticism about injections that have not completed clinical trials and were studied in only dozens of pe
- Clearside Biomedical Announces FDA Acceptance of Investigational NDA for CLS-AX Administered in Suprachoroidal Spacehttps://modernod.com/news/clearside-biomedical-announces-fda-acceptance-of-investigational-nda-for-cls-ax-administered-in-suprachoroidal-space/2478140/Clearside Biomedical announced that the FDA has accepted its investigational new drug (IND) application for CLS-AX (axitinib injectable suspension), enabling initiation of a phase 1/2a clinical trial of CLS-AX in wet age-related macular degeneration (AMD) patients by the end of 20
- Johnson & Johnson Forges $1-Billion Pact to Supply US with COVID-19 Vaccinehttps://modernod.com/news/johnson-johnson-forges-1-billion-pact-to-supply-us-with-covid-19-vaccine/2478133/Johnson & Johnson said it entered into an agreement with the US government for the large-scale domestic manufacturing and delivery of 100 million doses of its investigational SARS-CoV-2 vaccine Ad26.COV2.S for use in the country. Specifically, the US Biomedical Advanced Research and Developme
- Palatin Technologies Completes Enrollment of Phase 2 Study for Dry Eye Disease Treatment Candidatehttps://modernod.com/news/palatin-technologies-announces-completion-of-enrollment-of-phase-2-study-with-pl9643-for-the-treatment-of-dry-eye-disease/2478124/Palatin Technologies announced completion of enrollment of its phase 2 study with PL9643 for the treatment of dry eye disease (DED). After delaying enrollment of new patient groups due to the COVID-19 pandemic, Palatin reinitiated enrollment in its PL9643 phase 2 clinical study in subjects
- Eyenuk Announces FDA Clearance for EyeArt Autonomous AI System for Diabetic Retinopathy Screeninghttps://modernod.com/news/eyenuk-announces-fda-clearance-for-eyeart-autonomous-ai-system-for-diabetic-retinopathy-screening/2478123/Eyenuk announced it has received 510(k) clearance by the FDA to market its EyeArt autonomous AI System for diabetic retinopathy. EyeArt is indicated for use by health care providers to automatically detect more than mild diabetic retinopathy (mtmDR) and vision-threatening diabetic retinopa
- Eli Lilly Starts Late-Stage Study of Neutralizing Antibody Against SARS-CoV-2 in Nursing Homeshttps://modernod.com/news/eli-lilly-starts-late-stage-study-of-neutralizing-antibody-against-sars-cov-2-in-nursing-homes/2478118/Eli Lilly announced the initiation of a phase 3 study investigating whether its antibody-based drug LY-CoV555 can help reduce the rate of SARS-CoV-2 infection and COVID-19 in long-term care facilities in the US. The company is developing the neutralizing IgG1 antibody, which